

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

- 1-4. (Cancelled)
5. (Currently amended) A method of treating diabetes with sulfonylurea secondary failure in a diabetic mammal with sulfonylurea secondary failure which comprises administering an effective amount of a dipeptidyl peptidase IV inhibitor to the mammal.
6. (Cancelled)
7. (Cancelled)
8. (Original) A method of promoting insulin secretion in a diabetic patient with sulfonylurea secondary failure which comprises administering an effective amount of a dipeptidyl dipeptidase IV inhibitor to the patient.
9. (New) The method according to Claim 5 wherein the sulfonylurea secondary failure is ascribable to a sulfonylurea compound.
10. (New) The method according to Claim 5 wherein the sulfonylurea secondary failure is ascribable to a fast-acting insulin secretagogue.
11. (New) The method according to Claim 8 wherein the sulfonylurea secondary failure is ascribable to a sulfonylurea compound.
12. (New) The method according to Claim 8 wherein the sulfonylurea secondary failure is ascribable to a fast-acting insulin secretagogue.